Macrogenics Inc (NASDAQ:MGNX)
| Market Cap | 220.25M+99.4% |
| Revenue (ttm) | 167.67M+2.3% |
| Net Income | -14.59M+59.9% |
| EPS | -0.22+61.4% |
| Shares Out | 63.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 131,952.55 |
| Open | 3.51 |
| Previous Close | 3.55 |
| Day's Range | 3.41 - 3.59 |
| 52-Week Range | 1.29 - 5.08 |
| Beta | 1.21 |
| Analysts | Buy |
| Price Target | 6.00(+73.16%) |
| Earnings Date | Nov 11, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About MGNX
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$MGNX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in MGNX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MGNX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MGNX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New MGNX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MGNX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in MGNX
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $7.68M |
| IWMiShares Russell 2000 ETF | $5.76M |
| VXFVanguard Extended Market ETF | $2.66M |
| IWOiShares Russell 2000 Growth ETF | $1.89M |
| VTWOVanguard Russell 2000 ETF | $1.44M |
| FESMFidelity Enhanced Small Cap ETF | $1.15M |
Estimated from each fund’s disclosed top holdings × AUM
MGNX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from MGNX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score